New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer.
BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer. NPJ vaccines Valanparambil, R. M., Lai, L., Johns, M. A., Davis-Gardner, M., Linderman, S. L., McPherson, T. O., Chang, A., Akhtar, A., Gamarra, E. L., Matia, H., McCook-Veal, A. A., Switchenko, J., Nasti, T. H., Green, F., Saini, M., Wieland, A., Pinsky, B. A., Solis, D., Dhodapkar, M. V., Carlisle, J., Ramalingam, S., Ahmed, R., Suthar, M. S. 2023; 8 (1): 179Abstract
This study reports that most patients with NSCLC had a significant increase in the nAb response to the currently circulating Omicron variants after bivalent booster vaccination and had Ab titers comparable to healthy participants. Interestingly, though the durability of the nAb response persisted in most of the healthy participants, patients with NSCLC had significantly reduced nAb titers after 4-6 months of vaccination. Our data highlight the importance of COVID-19 bivalent booster vaccination as the standard of care for patients with NSCLC given the evolution of new variants of concern.
View details for DOI 10.1038/s41541-023-00779-8
View details for PubMedID 37990024
View details for PubMedCentralID PMC10663480